Pfizer Strikes $70 Billion Deal with U.S. to Expand Its mRNA Empire, Lower Drug Prices
‘Landmark agreement’ lets Pfizer expand its disastrous mRNA platform — sweeping a massive trail of death and destruction under the rug.
Pfizer announced a “landmark agreement” with the Trump Administration. The press release promised lower drug costs and a revival of U.S. manufacturing. President Donald Trump touted that Pfizer would cut Medicaid drug prices for low-income Americans and sell new medicines at a “most-favored-nation” price — but only in exchange for tariff relief.
In reality, it appears to be a multi-billion dollar effort to entrench Pfizer’s failed gene-transfer platforms for decades to come.
- Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs
- Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S.
- Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology
Pfizer itself spelled it out:
“With this agreement in place, Pfizer can fully focus on delivering the next generation of cures… in areas like oncology, obesity, vaccines, and inflammation and immunology.”
This comes after Pfizer’s COVID-19 gene-based products have already been linked to catastrophic injuries, deaths, and disabilities worldwide. Instead of scrutiny, the company is rewarded with protection and growth.
https://www.thefocalpoints.com/p/pfizer-strikes-70-billion-deal-with
This seems SERIOUSLY wrong and yet RFKjr was an integral part of the Press Announcement…………….
https://x.com/SenseReceptor/status/1973071002834755760?t=KfVnYIFL9N1skvCWFF-cCw&s=19
Bourla is a disgusting monster.
the Wall Street Journal ran a story headlined, “White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal.”
image 13.png
In a dramatic Oval Office meeting with his health cabinet and Pfizer’s cobra-like and oddly twitching CEO Albert Bourla, President Trump announced a new government portal expected to launch in early 2026 at the url TrumpRx.gov. It will let consumers buy drugs directly from manufacturers at steeply reduced prices, bypassing traditional middlemen like pharmacies, and paying in cash— thereby bypassing insurance channels and related costs.
Trump said Pfizer agreed to offer some of its most popular drugs on the platform at steep discounts, ranging from 50% to 100% off.
Also and separately, President Trump announced that Pfizer would now offer its drugs to the government at its “most favored nation” price, meaning the lowest price that any other country pays. And Pfizer must invest $70 million in new domestic R&D facilities. In return, Pfizer only got a 3-year waiver of new national security tariffs.
“This is something Democrats have wanted for 20 years, Republicans have wanted for 20 years,” Secretary Kennedy said during the meeting.
At some point during the announcement, though everyone including Bourla was smiling and nodding, one got the distinct impression that Pfizer was being punished for something. The MFN deal could cost the company billions.
However, Pfizer’s stock rose +6.8%, probably reflecting the market’s relief that Trump wasn’t planning on crushing the covid jabmaker’s snakey head. Reassuring investors, Pfizer did not update its financial guidance ahead of the meeting, suggesting it does not expect losses. It may, for example, plan to increase drug prices charged in other countries to offset the new domestic costs. Or, by selling drugs direct-to-consumer, and thereby avoiding pharmacies, pharma companies may net higher profit margins even though consumers see lower prices.
The sad truth is Pfizer is too big to kill; it makes hundreds of important drugs and is one of the biggest and most critical drugmakers in America.
Trump said the administration is working with other drugmakers to soon secure “similar agreements,” at one point mentioning Eli Lilly. “I said if we don’t make a deal, we’re going to tariff them an extra 5, 6, 7, 8 percent,” Trump said of negotiations with drug companies. FDA Commissioner Marty Makary said drugmakers who offer price concessions or move manufacturing to the U.S. would be eligible for his agency’s new voucher program that speeds drug approvals.
Carrots and sticks.
One party complains about the high cost of healthcare and petulantly shuts down the government. The other party negotiates most-favored-nation drug prices and launches a direct-to-consumer pharmaceuticals website all in the same day.
JEFF CHILDERS
Secrecy Over Trump-Pfizer Deal Sparks FOIA Demands and Public Outcry
Pfizer’s stock jumped Tuesday after CEO Albert Bourla and President Donald Trump announced a deal to lower U.S. drug prices and invest $70 billion in domestic manufacturing, while shielding the company from tariffs. Critics blasted the lack of transparency, with watchdog groups filing FOIA requests to uncover the agreement’s undisclosed terms.
Children’s Health Defense (CHD) CEO Mary Holland said it was “troubling” for the Trump administration to keep the details of its agreement with Pfizer confidential. Though arguably legal, the move “completely undermines” the administration’s commitment to transparency, she said, adding:
“The failure to provide any details of the U.S.-Pfizer pricing and tariff exemption deal is even more egregious in light of Pfizer’s long record of past criminal conduct and its knowing role in producing mRNA gene therapies, marketed as vaccines, that caused thousands of deaths and injuries.
“Pfizer knew that its mRNA shots neither stopped infection nor transmission.
“CHD stands firmly for a recall of the mRNA products currently on the market. The Vaccine Adverse Event Reporting System makes perfectly clear that these products are unsafe.”
CHD Chief Scientific Officer Brian Hooker agreed. “There really needs to be a ‘full stop’ with Pfizer, period, given the drugmaker’s duplicitous behavior around the COVID-19 jab.”
The federal government should be investigating Pfizer, not collaborating with it, Hooker said. “No transparency, no deal.”
https://childrenshealthdefense.org/defender/secrecy-over-trump-pfizer-deal-sparks-foia-demands-public-outcry/?